🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Allbirds And 3 Other Stocks Under $2 Insiders Are Aggressively Buying

Published 17/03/2023, 11:13
© Reuters.  Allbirds And 3 Other Stocks Under $2 Insiders Are Aggressively Buying
IXIC
-
SFES
-
BIRD
-

Benzinga - The Dow Jones closed higher by more than 350 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Safeguard Scientifics

  • The Trade: Safeguard Scientifics, Inc. (NASDAQ: SFE) 10% owner Thomas A. Satterfield acquired a total of 127,078 shares an average price of $1.79. To acquire these shares, it cost around $226.98 thousand.
  • What’s Happening: Safeguard Scientifics posted a Q4 loss of $0.30 per share.
  • What Safeguard Scientifics Does: Safeguard Scientifics Inc is engaged in the development of early- and growth-stage businesses by providing capital and relevant expertise to fuel the growth of an attractive portfolio of technology-enabled healthcare, digital media, and other companies.
ReWalk Robotics
  • The Trade: ReWalk Robotics Ltd. (NASDAQ: RWLK) CEO Lawrence J Jasinski acquired a total 15,000 shares at an average price of $0.72. The insider spent around $10.81 thousand to buy those shares.
  • What’s Happening: ReWalk announced the FDA clearance of ReWalk Personal Exoskeleton for use on stairs and curbs in US.
  • What ReWalk Robotics Does: ReWalk Robotics Ltd is an Israel based medical device company.
Check This Out: Top 4 Tech Stocks That That You May Want To Dump In March

Sonnet BioTherapeutics

  • The Trade: Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) Director, Chairman, President and CEO Pankaj Mohan acquired a total of 60,000 shares at an average price of $0.59. To acquire these shares, it cost around $35.1 thousand.
  • What’s Happening: Sonnet BioTherapeutics posted a Q1 loss of $0.80 per share.
  • What Sonnet BioTherapeutics Does: Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company.
Don’t forget to check out our premarket coverage here

Allbirds

  • The Trade: Allbirds, Inc. (NASDAQ: BIRD) Director Dan Levitan acquired a total of 75,796 shares at an average price of $1.08. The insider spent $81.86 thousand to buy those shares.
  • What’s Happening: Allbirds reported worse-than-expected Q4 financial results.
  • What Allbirds Does: Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.